Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Liabilities: 2019-2024

Historic Total Liabilities for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $133.6 million.

  • C4 Therapeutics' Total Liabilities fell 16.73% to $111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.1 million, marking a year-over-year decrease of 16.73%. This contributed to the annual value of $133.6 million for FY2024, which is 2.52% up from last year.
  • Per C4 Therapeutics' latest filing, its Total Liabilities stood at $133.6 million for FY2024, which was up 2.52% from $130.3 million recorded in FY2023.
  • C4 Therapeutics' Total Liabilities' 5-year high stood at $141.6 million during FY2022, with a 5-year trough of $117.2 million in FY2021.
  • In the last 3 years, C4 Therapeutics' Total Liabilities had a median value of $133.6 million in 2024 and averaged $135.2 million.
  • Per our database at Business Quant, C4 Therapeutics' Total Liabilities rose by 20.87% in 2022 and then declined by 7.96% in 2023.
  • C4 Therapeutics' Total Liabilities (Yearly) stood at $119.3 million in 2020, then fell by 1.83% to $117.2 million in 2021, then grew by 20.87% to $141.6 million in 2022, then declined by 7.96% to $130.3 million in 2023, then climbed by 2.52% to $133.6 million in 2024.